APA (7th ed.) Citation

XY, P., CW, T., IR, L., JM, C., SW, F., T, P., . . . BE, Y. (2022). Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 75(12), 2088. https://doi.org/10.1093/cid/ciac345

Chicago Style (17th ed.) Citation

XY, Poh, et al. "Antibody Response of Heterologous Vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 75, no. 12 (2022): 2088. https://doi.org/10.1093/cid/ciac345.

MLA (9th ed.) Citation

XY, Poh, et al. "Antibody Response of Heterologous Vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, vol. 75, no. 12, 2022, p. 2088, https://doi.org/10.1093/cid/ciac345.